Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia

Perini, Guilherme Fleury; Santos, Fábio Pires de Souza; Esteves, Iracema; Nascimento, Claudia Mac-Donald Bley do; Rodrigues, Morgani; Assis, Reijane Alves de; Helman, Ricardo; Kutner, José Mauro; Ribeiro, Andreza Alice Feitosa; Hamerschlak, Nelson

doi:10.1590/s1679-45082011ao1987

Einstein (São Paulo)

2011

DOI: 10.1590/s1679-45082011ao1987

|View full text |Cite

Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia

Guilherme Fleury Perini

Fábio Pires de Souza Santos

Iracema Esteves

et al.

Abstract: gemtuzumab ozogamycin combined with chemotherapy is a feasible treatment regimen in acute myeloid leukemia patients. However, further studies are necessary to clarify which subgroup of patients may beneft from this treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia

Wang²,

Gao

et al. 2020

MRMC

View full text Add to dashboard Cite

First stage human clinical trial (CTR20150246) for HAO472, the L-alanine-(14-oridonin) ester trifluoroacetate, was conducted by a Chinese company, Hengrui Medicine Co. Ltd, to develop a new treatment for acute myelogenous leukemia. Two patents, WO2015180549A1 and CN201410047904.X, covered the development of the I-type crystal, stability experiment, conversion rate research, bioavailability experiment, safety assessment, and solubility study. HAO472 hewed out new avenues to explore the therapeutic properties of oridonin derivatives and develop promising treatment of cancer originated from naturally derived drug candidates. Herein, we sought to overview recent progress of the synthetic, physiological, and pharmacological investigations of oridonin and its derivatives, aiming to disclose the therapeutic potentials and broaden the platform for the discovery of new anticancer drugs.

show abstract

Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia

Wang²,

Gao

et al. 2020

MRMC

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

334 Leonard St

Brooklyn, NY 11211

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia

Abstract: gemtuzumab ozogamycin combined with chemotherapy is a feasible treatment regimen in acute myeloid leukemia patients. However, further studies are necessary to clarify which subgroup of patients may beneft from this treatment.

Cited by 1 publication

References 25 publications

Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia

Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia

Contact Info

Product

Resources

About